Some investors might love biotech stocks for their lottery ticket-like returns when a company strikes medical gold. A lottery ticket, however, costs only …
Celldex Therapeutics, Inc. (NASDAQ:CLDX) presented data on new product candidate CDX-1140, a fully human antibody targeted to CD40 that has demonstrated potent agonist …
Cowen’s healthcare analyst Boris Peaker came out with an update on Celldex Therapeutics (NASDAQ:CLDX), following yesterday’s news that the company and partner Bristol Myers-Squibb initiated a phase 1/2 …